Bispecific antibody Phase 2 deals command this upfront

Bispecific antibodies have emerged as a dominant force in immuno-oncology licensing. Their ability to engage multiple targets simultaneously creates compelling clinical differentiation, and deal terms reflect the breadth of potential indications and combination strategies.

Based on analysis of 600+ biopharma licensing deals from 2020-2026